文献速递慢性肾脏病血液净化与透析

尿毒症毒素、慢性肾脏病与认知功能障碍

Uremic Toxins, CKD, and Cognitive Dysfunction.
PubMed 文献 · J Am Soc Nephrol · 2025-02-26

该综述总结了近5年关于慢性肾脏病相关认知障碍的文献,重点讨论尿毒症毒素的直接和间接作用、脑损伤机制以及与阿尔茨海默病的重叠。透析依赖患者的认知障碍患病率是年龄匹配对照的两倍,综述还汇总了AST-120、CH-223191等治疗干预及转化研究进展。

要点

  • CKD患者认知障碍患病率20%-70%,透析依赖者为年龄匹配对照的两倍。
  • 尿毒症毒素通过脑氧化应激、神经炎症和血脑屏障功能障碍致病。
  • 潜在干预包括AST-120、CH-223191、运动、补充剂和肾移植等。

核心结论

  • CKD相关认知障碍是常见疾病,仍需科学进展以保护认知功能并改善患者生活。

研究设计与样本

  • 综述文章,总结近5年关于肾脏-脑轴、CKD相关认知障碍机制及治疗研究的文献。

主要发现

  • CKD患者认知障碍患病率为20%-70%,透析依赖患者患病率为年龄匹配对照的两倍。
  • 尿毒症毒素相关致病过程包括脑氧化应激、神经炎症和血脑屏障功能障碍。
  • CKD相关认知障碍与阿尔茨海默病及其他神经退行性疾病存在重叠。

关键数值与推荐

  • 综述汇总的治疗干预包括AST-120、CH-223191、triarylmethane-34、anakinra、marimastat、运动、补充剂和肾移植。

临床怎么用

  • 临床应关注CKD尤其是透析患者的认知功能评估。
  • 尿毒症毒素相关机制提示潜在治疗靶点,但需进一步转化验证。

局限性

  • CKD相关认知障碍仍存在知识空白,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cognitive impairment involves alterations to one's cognitive status that affects everyday life. Individuals with CKD, and particularly kidney failure, experience higher rates of cognitive impairment (20%-70%) compared with the general population. The highest prevalence is described in kidney failure such that dialysis-dependent patients have twice the prevalence of age-matched controls. In the past 5 years, the number of investigations examining the "kidney-brain axis," mechanisms of CKD-related cognitive impairment, and potential therapeutics have exponentially increased. This review article summarizes recent literature on direct and indirect effects of CKD-associated cognitive impairment with emphasis on uremic toxins; brain injury mechanisms; overlap between CKD-associated cognitive impairment, Alzheimer's disease, and other neurodegenerative diseases. Reviewed therapeutic interventions include AST-120 (indoxyl sulfate absorbent), CH-223191 (aryl hydrocarbon receptor antagonist), triarylmethane-34 (Kca3.1-specific inhibitor), anakinra (IL-1R inhibitor), marimastat, exercise, supplements, and kidney transplantation. Special focus is placed on translational studies examining uremic toxin-associated pathogenic processes, including brain oxidative stress, neuroinflammation, and blood-brain barrier dysfunction through in vitro and in vivo models of CKD-associated brain injury. Finally, future research directions are suggested, including targeting of cellular senescence abundance with senotherapeutics and capitalizing on anti-inflammatory effects of regenerative, cell-based therapeutics ( e.g ., mesenchymal stem cells and extracellular vesicles), and use of aged murine models. Collectively, CKD-associated cognitive impairment represents a prevalent condition for which remaining knowledge gaps exist, and scientific advancements are needed to preserve cognitive function and improve the lives of individuals with CKD.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Andrews TD, Day GS, Irani SR, et al. Uremic Toxins, CKD, and Cognitive Dysfunction. J Am Soc Nephrol. 2025. PMID: 40009460. doi:10.1681/ASN.0000000675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。